Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical firm, announced that CEO Jill C. Milne, Ph.D., will present information on their lead program STAR-0215 at the Jefferies London Healthcare Conference. The presentation will be available on-demand from November 18, 3:00 am ET to November 19, 12:00 pm ET. Attendees can access the webcast via the Investors section of Astria's website and at this link. An archived replay will be available for 30 days following the event.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on lead program STAR-0215 at the upcoming virtual Jefferies London Healthcare Conference.

The presentation will be available to all conference attendees on-demand beginning on Thursday, November 18, at 3:00am ET through Friday, November 19, at 12:00pm ET.

A webcast of the event can be accessed from the Investors section of www.astriatx.com and at the following link: https://wsw.com/webcast/jeff201/atxs/1865664. An archived replay will be available for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005334/en/

Astria:

Investor relations:

Andrea Matthews

investors@astriatx.com

Media:

Elizabeth Higgins

media@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What is the date of the Astria Therapeutics presentation at the Jefferies London Healthcare Conference?

The presentation will be available on-demand from November 18, 3:00 am ET to November 19, 12:00 pm ET.

Who is presenting at the Jefferies London Healthcare Conference for Astria Therapeutics?

CEO Jill C. Milne, Ph.D., will present information on STAR-0215.

Where can I access the webcast for the Astria Therapeutics presentation?

The webcast can be accessed from the Investors section of Astria's website and directly at https://wsw.com/webcast/jeff201/atxs/1865664.

How long will the presentation from Astria Therapeutics be available for replay?

An archived replay will be available for 30 days following the event.

What is STAR-0215 being developed for by Astria Therapeutics?

STAR-0215 is being developed for the treatment of hereditary angioedema.